Prevents postoperative thromboembolic complications of cardiac valve replacement. ANDA 40874, held by Zydus Pharms USA Inc. Dipyridamole.
As of Nov 16, 2026, ANDA 40874 (Dipyridamole), held by Zydus Pharms USA Inc, was first approved by FDA on Jan 28, 2008, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Dipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 28, 2008 | Original application | Approved | None posted |
| Dipyridamole25MG · tablet;oral | Dipyridamole | Rx |
| Dipyridamole50MG · tablet;oral | Dipyridamole | Rx |
| Dipyridamole75MG · tablet;oral | Dipyridamole | Rx |
| Jan 27, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 27, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 28, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters